SAN DIEGO -- Treatment with hydroxyurea led to more hematologic dose-limiting toxicities (DLTs) compared with placebo in patients with hemoglobin SC, a milder form of sickle cell disease (SCD), a ...

Painful symptoms of sickle-cell disease begin within the first year of life. Hydroxyurea (hydroxycarbamide) has been shown to reduce pain in adults (N Engl J Med. 1995;332:1317-1322) and has been ...

Researchers have revealed that hydroxyurea significantly reduces infections in children with sickle cell anemia. Their findings enhance strong evidence of hydroxyurea's effectiveness and could ...

Hydroxyurea remains effective over the long term among children with sickle cell disease, real-world data suggested. The average time on hydroxyurea was 5 years, with many children on the therapy for ...

Sickle cell disease, while rare, is the most common inherited blood disorder and affects over 100,000 people in the United States, more than 90% of whom are Black according to the Centers for Disease ...

Sickle cell disease (SCD) is a pressing global health issue, with rising cases and mortality, especially in low- and middle-income countries (LMICs). Hydroxyurea, a cost-effective treatment for SCD, ...

Fewer ED visits per year and fewer hospital days per year seen in association with hydroxyurea use. HealthDay News — For children with sickle cell anemia (SCA), hydroxyurea has sustained clinical ...

In female patients living with sickle cell disease (SCD), hydroxyurea had no effect on ovarian reserve, suggesting that fertility preservation measures prior to treatment may be unnecessary, according ...

Please provide your email address to receive an email when new articles are posted on . Three-quarters of women who became pregnant during hydroxyurea therapy had live births. Researchers observed no ...

Please provide your email address to receive an email when new articles are posted on . Use of hydroxyurea did not reduce ovarian reserve among girls and young women with sickle cell disease.

Zinc for Infection Prevention in Sickle Cell Anemia study leaders Chandy John, far left; Ruth Namazzi, second from right; and Robert Opoka, far right; with Justin Brown, second from left, and Aaron ...